Breaking News, Financial News

Societal CDMO 4Q Financial Results

Revenue up 9% to $24.3 million.

Societal CDMO  4Q Revenues: $24.3 million (+9%) 4Q Loss: $9.2 million (loss of $2.4 million 4Q21) FY Revenues: $90.2 million (+20 %) FY Loss: $19.9 million (loss of $11.4 million FY21) Comments: Growth in the quarter was primarily driven by an increase in European Ritalin LA demand from the company’s new customer InfectoPharm, and an increase in revenue from the company’s largest commercial customer Teva, correlated with pull through in demand resulting from market share gains against the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters